IMA
ImageneBio Inc
NASDAQ · USHealthcareBiotechnology
$5.73+6.51%
Price as of Jul 20, 2026
IMA growth
ImageneBio Inc growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- —
- EBITDA
- -7.8%
- EBIT
- -8.5%
- EPS
- —
- Free cash flow
- -36.1%
- Operating cash flow
- -36.1%
Forward estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +42.3%
Three-year CAGR
- Revenue
- -62.9%
- EBITDA
- -27.5%
- EBIT
- -30.9%
- Net income
- -24.0%
- EPS
- —
- Free cash flow
- -4.0%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.